A Phase I Multiple Ascending Dose Study of BMS-844203 (CT-322) Monotherapy in Japanese Patients With Solid Tumors.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2012
At a glance
- Drugs Pegdinetanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 06 Feb 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 28 Apr 2011 Planned end date changed from 1 Jul 2011 to 1 Jan 2015 as reported by ClinicalTrials.gov.